PIT565

Phase 1Biologic

Novartis

PIT565 is one of 75 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

SystemicActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

SystemicPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Cimzia

UCB

Preclinical

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

Arcoxia

Novartis

Preclinical

4 5

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 6

Ilaris

Novartis

Preclinical

3 7

Actos

Takeda

Preclinical

2 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Cataflam

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Systemic

NCT06335979

Q2 2028

Phase 1Active, not recruiting

Rheumatoid Arthritis

NCT07029555

Clinical

Trials by Indication[1]

B-cell Malignancies1 trial

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT05397496·61 enrolled

Systemic1 trial

A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT06335979·54 enrolled

Rheumatoid Arthritis1 trial

A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT07029555·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PIT565. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PIT565 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PIT565. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Novartis

PIT565

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

B-cell Malignancies1 trial

Systemic1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News